PDF
ePub
Citation
Print
Abstract
In patients with detectable virus at the time of liver transplantation, hepatitis C virus (HCV) infection always recurs on the graft, and 30% of patients have an aggressive clinical and histologic course with increased morbidity, mortality, and graft loss. Moreover, in some transplantation patients, recurrent HCV infection leads to an aggressive course of disease known as fibrosing cholestatic hepatitis, which is characterized by hepatic decompensation and death. Liver allograft and recipient survival can be substantially improved with successful eradication of HCV. Recent advances in direct-acting antiviral agents have revolutionized the management of HCV infection, and a number of these agents have shown high sustained virological responses, shorter durations of treatment, and much improved tolerability when compared with previous pegylated interferon based therapies in liver transplant settings.
REFERENCES
1). Liang TJ., Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013. 368:1907–17.
2). Bunchorntavakul C., Tanwandee T. Treatment of Chronic Hepatitis C in Special Populations. Gastroenterol Clin North Am. 2015. 44:883–900.
3). Rodriguez-Luna H., Khatib A., Sharma P., De Petris G., Williams JW., Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004. 77:190–4.
4). Samuel D., Bizollon T., Feray C., Roche B., Ahmed SN., Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003. 124:642–50.
5). Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002. 35:680–7.
6). Fortune BE., Martinez-Camacho A., Kreidler S., Gralla J., Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transplant Int. 2015. 28:980–9.
7). Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008. 14(Suppl 2):S36–44.
8). Joshi D., Carey I., Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther. 2013. 37:659–71.
9). European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol [in press 2016 Sep 12].
10). Omata M., Kanda T., Wei L., Yu ML., Chuang WL., Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016. 10:702–26.
11). van der Meer AJ., Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016. 65(1 Suppl):S95–S108.
12). Charlton M., Gane E., Manns MP., Brown RS Jr., Curry MP., Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015. 148:108–17.
13). Forns X., Charlton M., Denning J., McHutchison JG., Symonds WT., Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015. 61:1485–94.
14). Charlton M., Everson GT., Flamm SL., Kumar P., Landis C., Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015. 149:649–59.
15). Manns M., Samuel D., Gane EJ., Mutimer D., McCaughan G., Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016. 16:685–97.
16). Poordad F., Schiff ER., Vierling JM., Landis C., Fontana RJ., Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016. 63:1493–505.
17). Coilly A., Fougerou-Leurent C., de Ledinghen V., Hou-ssel-Debry P., Duvoux C., Di Martino V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. J Hepatol. 2016. 65:711–8.
18). Kwo PY., Mantry PS., Coakley E., Te HS., Vargas HE., Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014. 371:2375–82.
19). AASLD/IDSA guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015. 62:932–54.
20). Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016. 22:76–139.
21). Dick TB., Lindberg LS., Ramirez DD., Charlton MR. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016. 63:634–43.
Table 1.
Recommended HCV treatment for patients in the liver transplantation setting
Abbreviations: KASL, Korean Association for the Study of the Liver; AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; EASL, European Association for the Study of the Liver; SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; R, weight-based ribavirin; R∗, ribavirin started from 600 mg/d; OPr, ombitasvir/paritaprevir/ritonavir; D, dasabuvir. Adapted from reference(9,19,20).
XML Download